NovaBay Pharmaceuticals Inc
NBY
View Detailed Chart
1.100USD
+0.010+0.92%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
6.40MMarket Cap
2.76P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.92%
5 Days
-12.70%
1 Month
-19.12%
6 Months
+87.52%
Year to Date
+83.03%
1 Year
+45.50%
View Detailed Chart
TradingKey Stock Score of NovaBay Pharmaceuticals Inc
Currency: USD Updated: 2025-11-04Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NovaBay Pharmaceuticals Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.850
Target Price
-18.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NovaBay Pharmaceuticals Inc Highlights
StrengthsRisks
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78M.
Overvalued
The company’s latest PE is 0.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.33M shares, decreasing 8.74% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.07.
NovaBay Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
NovaBay Pharmaceuticals Inc Info
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Ticker SymbolNBY
CompanyNovaBay Pharmaceuticals Inc
CEOMr. David E. Lazar
Websitehttps://novabay.com/
Related Instruments
+1.15%
+0.32%
+1.85%
+0.38%
+0.93%
+1.66%
-1.75%
+0.13%
+0.78%
-1.46%
-1.88%
-1.02%
+2.61%
+1.01%
-0.93%
-0.64%
0.00%
-2.22%
-2.44%
-13.78%Popular Symbols
